Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01812447 · ClinicalTrials.gov registry record · NA
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A NA study, sponsored by Olympus Corporation of the Americas.
- Completed
- Registry status
- NA
- Development phase
- 172
- Enrollment target
NCT01812447: Completed NA study, sponsored by Olympus Corporation of the Americas.
NCT01812447 is a NA study that has completed, run by Olympus Corporation of the Americas. The registered enrollment target is 172 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01812447, a NA study, has completed, sponsored by Olympus Corporation of the Americas.
- COMPLETED
- Registry status
- NA
- Development phase
- 172 participants
- Enrollment target
Study Summary
EMPROVE is a multicenter, prospective, randomized, controlled study designed to evaluate the safety and long-term effectiveness of the Spiration Valve System in patients with emphysema. Patients appropriate for the EMPROVE study are those who are currently on medical treatment but still symptomatic. EMPROVE also accepts α-1 antitrypsin deficiency patients.
Interventions
- OTHER Medical Management
- DEVICE Spiration Valve System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2013-06 |
| Est. Completion | 2022-08 |
| Phase | NA |
What the finished NCT01812447 record still lists
NCT01812447 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Medical Management is the first listed.
NCT01812447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01812447 about?
NCT01812447 is a clinical study titled "Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function". EMPROVE is a multicenter, prospective, randomized, controlled study designed to evaluate the safety and long-term effectiveness of the Spiration Valve System in patients with emphysema. Patients appropriate for the EMPROVE study are those who are currently on medical treatment but still symptomatic...
What is the current status of trial NCT01812447?
This trial is currently completed. It is a NA study. The enrollment target is 172 participants. The study started on 2013-06. Estimated completion is 2022-08.
What interventions are being tested in trial NCT01812447?
The interventions under investigation include: Medical Management (OTHER), Spiration Valve System (DEVICE).
Who is sponsoring clinical trial NCT01812447?
This trial is sponsored by Olympus Corporation of the Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01812447's enrollment target sits among peer trials
172 612th of 2000 higher than 1,389 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia